ERBB2 and breast carcinoma: As a dual kinase inhibitor of human epidermal growth receptors EGFR and HER2 for breast cancer treatment, lapatinib is a substrate for ABCG2 and P-glycoprotein (P-gp), another ATP-binding cassette family protein commonly involved in multidrug resistance to cancer chemotherapy.20